Evidence map›Paper›PMID 34881080›Full record

ReviewAging and disease2021

Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease.

Morteza Abyadeh, Vivek Gupta, Veer Gupta, Nitin Chitranshi, Yunqi Wu, Ardeshir Amirkhani, Anna Meyfour, Samran Sheriff, Ting Shen, Kunal Dhiman and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Aging and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. The effect of fingolimod (FTY720) protecting the retina of rats from light-induced retinal degeneration (LIRD).Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Morteza Abyadeh1Cell Science Research Center, Department of Molecular Systems Biology, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Vivek Gupta2Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.
Veer Gupta3School of Medicine, Deakin University, VIC, Australia.
Nitin Chitranshi2Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.
Yunqi Wu4Australian Proteome Analysis Facility, Macquarie University, Macquarie Park, NSW, Australia.
Ardeshir Amirkhani4Australian Proteome Analysis Facility, Macquarie University, Macquarie Park, NSW, Australia.
Anna Meyfour5Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Samran Sheriff2Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.
Ting Shen2Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.
Kunal Dhiman3School of Medicine, Deakin University, VIC, Australia.
H Salekdeh Ghasem6Department of Molecular Sciences, Macquarie University, Macquarie Park, NSW, Australia.
A Haynes Paul6Department of Molecular Sciences, Macquarie University, Macquarie Park, NSW, Australia.
L Graham Stuart2Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.
Mehdi Mirzaei2Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is the leading cause of dementia that has remained a major medical, sociocultural and economical challenge globally. Previously developed treatments like anticholinesterase inhibitors (AChEIs) and N-methyl-D-aspartate receptor (NMDAR) antagonists only provide short-term symptomatic improvement and do not prevent progression. Repeated setbacks and failures over the past 25 years in AD clinical trials have hindered efforts to develop effective AD treatments. Fortunately, Aducanumab, a specific anti-amyloid β antibody, has shown promising clinical results and was recently approved by the Food and Drug Administration (FDA) through an accelerated approval pathway. This has raised hopes for AD patients; however post-approval trials are necessary to estimate the true scope of its clinical benefits. We have reviewed several AD clinical studies and summarized the experience to date with Aducanumab and two other potential AD drugs including Zagotenemab (an anti-tau antibody) and Pioglitazone (nuclear Peroxisome-Proliferator Activated Receptor γ (PPARγ) agonist). These have shown mixed results so far and the next few years will be critical to elucidate and interpret their broad long-term protective effects. A concerted effort is required to understand and strengthen the translation of pre-clinical findings from these drugs to routine clinical practice.

Indexed as

AducanumabAlzheimer’s diseasePioglitazoneZagotenemab

Identifiers

PMID34881080
PMCPMC8612603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.